BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12975039)

  • 21. PAX8-PPARgamma oncogene in follicular thyroid tumors: RT-PCR and immunohistochemical analyses.
    Pauzar B; Karner I; Glavas-Obrovac L; Stefanić M; Dmitrović B
    Coll Antropol; 2012 Nov; 36 Suppl 2():79-82. PubMed ID: 23397760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?
    Sugg SL; Zheng L; Rosen IB; Freeman JL; Ezzat S; Asa SL
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3360-5. PubMed ID: 8784097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience.
    Bongiovanni M; Molinari F; Eszlinger M; Paschke R; Barizzi J; Merlo E; Giovanella L; Fasolini F; Cattaneo F; Ramelli F; Mazzucchelli L; Frattini M
    Cytopathology; 2015 Oct; 26(5):288-96. PubMed ID: 25487739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Oncogenes and thyroid tumors].
    Lacroix L; Soria JC; Bidart JM; Schlumberger M
    Bull Cancer; 2005 Jan; 92(1):37-43. PubMed ID: 15689324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
    McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.
    Foukakis T; Au AY; Wallin G; Geli J; Forsberg L; Clifton-Bligh R; Robinson BG; Lui WO; Zedenius J; Larsson C
    J Clin Endocrinol Metab; 2006 Mar; 91(3):1143-9. PubMed ID: 16352687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
    Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
    Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
    Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
    Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance.
    Acquaviva G; Visani M; Repaci A; Rhoden KJ; de Biase D; Pession A; Giovanni T
    Histopathology; 2018 Jan; 72(1):6-31. PubMed ID: 29239040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Caveolin-1 and caveolin-2,together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis.
    Aldred MA; Ginn-Pease ME; Morrison CD; Popkie AP; Gimm O; Hoang-Vu C; Krause U; Dralle H; Jhiang SM; Plass C; Eng C
    Cancer Res; 2003 Jun; 63(11):2864-71. PubMed ID: 12782592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
    Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
    Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The advances of molecular pathology of follicular thyroid carcinoma].
    Zhan Y; Cui QC
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):268-70. PubMed ID: 15256127
    [No Abstract]   [Full Text] [Related]  

  • 34. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic and biological subgroups of low-stage follicular thyroid cancer.
    French CA; Alexander EK; Cibas ES; Nose V; Laguette J; Faquin W; Garber J; Moore F; Fletcher JA; Larsen PR; Kroll TG
    Am J Pathol; 2003 Apr; 162(4):1053-60. PubMed ID: 12651598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours.
    Wojtas B; Pfeifer A; Oczko-Wojciechowska M; Krajewska J; Czarniecka A; Kukulska A; Eszlinger M; Musholt T; Stokowy T; Swierniak M; Stobiecka E; Chmielik E; Rusinek D; Tyszkiewicz T; Halczok M; Hauptmann S; Lange D; Jarzab M; Paschke R; Jarzab B
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28574441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas.
    Manenti G; Pilotti S; Re FC; Della Porta G; Pierotti MA
    Eur J Cancer; 1994; 30A(7):987-93. PubMed ID: 7946598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.
    Ulivieri A; Lavra L; Dominici R; Giacomelli L; Brunetti E; Sciacca L; Trovato M; Barresi G; Foukakis T; Jia-Jing L; Larsson C; Bartolazzi A; Sciacchitano S
    J Pathol; 2008 May; 215(1):87-96. PubMed ID: 18306168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.
    Lado-Abeal J; Celestino R; Bravo SB; Garcia-Rendueles ME; de la Calzada J; Castro I; Castro P; Espadinha C; Palos F; Soares P; Alvarez CV; Sobrinho-Simões M; Cameselle-Teijeiro J
    Endocr Relat Cancer; 2010 Sep; 17(3):599-610. PubMed ID: 20427420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.